



SDI Review Form 1.6

Journal Name:	British Journal of Pharmaceutical Research
Manuscript Number:	2013_BJPR_5633
Title of the Manuscript:	Pharmacovigilance Analysis of Adverse Psychiatric Events and Suicidality Reported for Roflumilast, an Add-On COPD Therapy
Type of the Article	Research Paper

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Compulsory REVISION comments	This is a well-written paper that generates hypotheses related to the preliminary findings that roflumilast may be associated with adverse psychiatric events. The analyses and the tables are very clearly presented and discussed.	
Minor REVISION comments	<ol style="list-style-type: none"> 1. Sentence on line 29 needs revision. 2. Figure 2: It is not clear what the colour bars with the scales below the actual figure will add. These are confusing and can be deleted. 	
Optional/General comments		

Reviewer Details:

Name:	Yohannes Tesfaigzi
Department, University & Country	Lovelace Respiratory Research Institute, COPD Program, USA